Work

Biomarker-based phase II study of sapanisertib (TAK-228), an mTORC1/2 inhibitor in patients with refractory metastatic renal cell carcinoma (mRCC).

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.6_suppl.306

Authors: Bradley Alexander McGregor, Elio Adib, Wanling Xie, Walter Michael Stadler, Yousef Zakharia, M Dror Michaelson, Ajjai Shivaram Alva, Subrina Farah, Amin Nassar, Lauren C Harshman, David J. Kwiatkowski, Rana R. McKay, Toni K. Choueiri

Institutions: Dana-Farber Cancer Institute, University of Chicago, University of Iowa, Massachusetts General Hospital, U-M Rogel Cancer Center, Harvard University, Dana-Farber/Harvard Cancer Center, Brigham and Women's Hospital, Moores Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3135761601

Cites:

Cited by: 1

Related to: 10